Two Jacks, One mission 🤓 Head on to the booth and get a chance to meet either one of them (both if you’re lucky, like me!) Continue tuning in for coverage of #ACR25 by the @RheumNow faculty and KOLs https://t.co/Y2pS8CpoH5

CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats Do you believe it? #ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP

#ACR25 Abstr#802 In #SLE pts with CLASI-A ≥8, pooled post-hoc analysis of Phase 2 RCT showed enpatoran, oral small molecule toll-like receptor 7/8-i impoved cutaneous response vs PBO as early as WK4. First-in-class promising therapy & warrant investigation in Phase 3 @RheumNow https://t.co/rn6NXdiGjD

Urinary proteomics reveals promising biomarkers for ankylosing spondylitis. PIK3IP1 & SDC1 levels were significantly elevated in AS patients, showing strong diagnostic performance (AUCs: 0.852 & 0.875). Combined with AMY1A, the multiplex panel reached an AUC of 0.973. Abstract https://t.co/YUulKFqj8V

Effect of BioDMARDs on Diabetes risk in 6400+ Psoriasis pts IL-23i and IL-17Ai associated w/ -lower risks of diabetes -Diabetic nephropathy -Stage 3–5 CKD and reduced risk compared to TNFi treated and bionaive pts Adjustment on several variables, but not disease severity https://t.co/TDIHXJOC2T

The benefits of exercise has been proven for most rheumatic diseases, and there are lots of good reasons why #ACR25 Brian Andonian @RheumNow https://t.co/IEErXL6ynL

What is my risk of developing proteinuria? Hopkins Lupus Cohort developed a risk score predicting 10-year risk of new-onset proteinuria after SLE dx (n=1,418) @RheumNow #ACR25 https://t.co/Z0zPrG2NJ3

#ACR25 Abstr#801 Post-hoc analysis of Phase 2 RCT showed longer duration on Ianalumab (IAN) is beneficial. More #SLE pts achieved LLDAS or DORIS remission and GC taper in IAN in blinded 28-wk phase + open label IAN for the next 24-week group vs PBO-Open Label IAN @RheumNow https://t.co/I1Ugfj3BBl

A retrospective study from Spain assessed the relationship bet HPV infxn & biologic tx in SLE pts 🔅 Prevalence of HPV 9.9% 🔅 No significant assocs bet HPV infxn, biologic tx, SLE-related dse variables & HPV RF progression Still, emphasize HPV screening #ACR25 @RheumNow Abs0659 https://t.co/1YusM1nYPr

#0777 Big news for VEXAS! 🎯 The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV